Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study

Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study

Abstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM....

Full description

Saved in:

Bibliographic Details
Main Authors:	Majid Jaberi-Douraki, Xuan Xu, Danai Dima, Sikander Ailawadhi, Faiz Anwer, Sandra Mazzoni, Jason Valent, Muhammad Hamza Habib, Jim E. Riviere, Shahzad Raza
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-12-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-01206-4
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
by: Mobina Golmohammadi, et al.
Published: (2025-08-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

Optimal control of vaccination dynamics during an influenza epidemic
by: Majid Jaberi-Douraki, et al.
Published: (2014-05-01)

Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database
by: Jiayu Shen, et al.
Published: (2025-06-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
by: Ricardo D. Parrondo, et al.
Published: (2020-01-01)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
by: Sikander Ailawadhi, et al.
Published: (2023-02-01)

Pharmacovigilance Data as a Trigger to Identify Antimicrobial Adverse Effects: A Study Using Reports from Basra Pharmacovigilance Centre
by: Sarah T Omran
Published: (2024-01-01)

MDDC: An R and Python package for adverse event identification in pharmacovigilance data
by: Anran Liu, et al.
Published: (2025-07-01)

Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles
by: Lijun Wang, et al.
Published: (2025-08-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Real-World Pharmacovigilance Analysis of Adverse Events Associated with Liposomal Bupivacaine and Bupivacaine
by: Chen DX, et al.
Published: (2025-04-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system
by: Bahadır Köylü, et al.
Published: (2025-03-01)

AI-driven pharmacovigilance: Enhancing adverse drug reaction detection with deep learning and NLP
by: Dr. Bharti Khemani, et al.
Published: (2025-12-01)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
by: Tianyu Chen, et al.
Published: (2025-05-01)

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
by: Yong Yu, et al.
Published: (2025-02-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Pharmacovigilance
by: B M Sattigeri, et al.
Published: (2015-07-01)

Understanding the Opioid Epidemic through Pharmacovigilance Signals: an Analysis of Pharmacovigilance Datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS) over 10 Years
by: S. Chiappini, et al.
Published: (2024-12-01)

Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database
by: Connor Frey
Published: (2024-12-01)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
by: He Chen, et al.
Published: (2025-05-01)

Effect of Ultraviolet Water Treatment on Survival and Growth of Escherichia coli in Recirculating Hydroponic Systems
by: Markanna Moore, et al.
Published: (2025-08-01)

Incidence of Adverse Events Related to Therapies with sodium iodine (131I): Contribution to the Pharmacovigilance in Brazil
by: Jaqueline Cardena Fernandes, et al.
Published: (2024-09-01)

Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers’ Experiences from Southern Highland Tanzania
by: Dorkasi L. Mwakawanga, et al.
Published: (2023-01-01)

Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
by: Jingkai Di, et al.
Published: (2025-07-01)

Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
by: Xu Y, et al.
Published: (2025-05-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
by: Dongdong Zhang, et al.
Published: (2024-12-01)

Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database.
by: Emma F Magavern, et al.
Published: (2025-03-01)

Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System
by: Ana Sofia Martins, et al.
Published: (2024-10-01)

Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program
by: Tinashe Mudzviti, et al.
Published: (2012-11-01)

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
by: Jiancheng Qian, et al.
Published: (2024-12-01)